UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 227

Sortiert nach

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

The New England journal of medicine, 2013-11, Vol.369 (19), p.1807-1818

2013

Link zum Volltext

Verfügbarkeit prüfen

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

The Lancet infectious diseases, 2012-02, Vol.12 (2), p.111-118

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

BMC infectious diseases, 2022-10, Vol.22 (1), p.1-782, Article 782

2022

Link zum Volltext

Verfügbarkeit prüfen

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

PloS one, 2019-10, Vol.14 (10), p.e0223181-e0223181

2019

Link zum Volltext

Verfügbarkeit prüfen

Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort

Journal of the International Association of Providers of AIDS Care, 2022-01, Vol.21, p.23259582221101815-23259582221101815

2022

Link zum Volltext

Verfügbarkeit prüfen

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care, 2022-01, Vol.21, p.232595822211402-23259582221140208

2022

Link zum Volltext

Verfügbarkeit prüfen

Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors

Clinical infectious diseases, 2005-01, Vol.40 (1), p.158-163

2005

Link zum Volltext

Verfügbarkeit prüfen

The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort

BMC public health, 2016-08, Vol.16 (1), p.878-878, Article 878

2016

Link zum Volltext

Verfügbarkeit prüfen

Efavirenz: a decade of clinical experience in the treatment of HIV

Journal of antimicrobial chemotherapy, 2009-11, Vol.64 (5), p.910-928

Maggiolo, Franco

2009

Link zum Volltext

Verfügbarkeit prüfen

Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART

PloS one, 2015-05, Vol.10 (5), p.e0124741-e0124741

2015

Link zum Volltext

Verfügbarkeit prüfen

Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV

iScience, 2024-01, Vol.27 (1), p.108673-108673, Article 108673

2024

Link zum Volltext

Verfügbarkeit prüfen

Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

BMC infectious diseases, 2018-06, Vol.18 (1), p.285-11, Article 285

2018

Link zum Volltext

Verfügbarkeit prüfen

Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study

PloS one, 2014-04, Vol.9 (4), p.e94768-e94768

2014

Link zum Volltext

Verfügbarkeit prüfen

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment

PloS one, 2016-09, Vol.11 (9), p.e0162320-e0162320

2016

Link zum Volltext

Verfügbarkeit prüfen

TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM ENSAIO CLÍNICO RANDOMIZADO (SALSA)

The Brazilian journal of infectious diseases, 2022-01, Vol.26, p.101720

2022

Link zum Volltext

Verfügbarkeit prüfen

Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy

Journal of clinical medicine, 2022-01, Vol.11 (2), p.471

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice

PloS one, 2016-10, Vol.11 (10), p.e0160761

2016

Link zum Volltext

Verfügbarkeit prüfen

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort

PloS one, 2016-06, Vol.11 (6), p.e0156360

2016

Link zum Volltext

Verfügbarkeit prüfen

Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection

Journal of medical virology, 2021-07, Vol.93 (7), p.4612-4615

2021

Link zum Volltext

Verfügbarkeit prüfen

Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C

Blood, 2002-06, Vol.99 (12), p.4588-4591

2002

Link zum Volltext

Verfügbarkeit prüfen

Increasing clinical virulence in two decades of the Italian HIV epidemic

PLoS pathogens, 2009-05, Vol.5 (5), p.e1000454-e1000454

2009

Link zum Volltext

Verfügbarkeit prüfen

Single-Tablet Regimens in HIV Therapy

Infectious diseases and therapy, 2014-06, Vol.3 (1), p.1-17

2014

Link zum Volltext

Verfügbarkeit prüfen

Abacavir + dolutegravir + lamivudine for the treatment of HIV

Expert opinion on pharmacotherapy, 2016-10, Vol.17 (15), p.2097-2106

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 227

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(206)
Mit Volltextzugriff
(188)

Publikationsform

Artikel
(224)
Berichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

Adherence to and Forgiveness of 3TC/DTG in a Real-World Cohort

Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide

Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Nonnucleoside Analogues or Protease Inhibitors

The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

Efavirenz: a decade of clinical experience in the treatment of HIV

Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART

Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV

Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015

Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment

TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM ENSAIO CLÍNICO RANDOMIZADO (SALSA)

Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy

Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort

Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection

Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C

Increasing clinical virulence in two decades of the Italian HIV epidemic

Single-Tablet Regimens in HIV Therapy

Abacavir + dolutegravir + lamivudine for the treatment of HIV

Suchergebnisse filtern